Rapid antigen test

Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU

Friday, June 11, 2021 - 12:25pm

Lateral flow antigen tests are intended to provide a cost effective and rapid means of identifying individuals with a high viral load that means they are more likely to infect others.

Key Points: 
  • Lateral flow antigen tests are intended to provide a cost effective and rapid means of identifying individuals with a high viral load that means they are more likely to infect others.
  • The clinical data for Avactas AffiDX SARS-CoV-2 antigen lateral flow test reported 20 April 2021, demonstrated 100% sensitivity for identifying infectious individuals with viral loads measured by PCR of Ct
  • The product registration by a Competent Authority in the EU allows the Company to sell the product in the EU for professional use.
  • Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: We are delighted to receive confirmation of the registration of the AffiDX SARS-CoV-2 antigen test in the EU.

USA Swimming Partners with BD to Provide COVID-19 Screening for the Olympic Trials and Other Competitive Swimming Events

Friday, June 11, 2021 - 11:50am

These tests will also be utilized at 2021-2022 USA Swimming events where testing is required.

Key Points: 
  • These tests will also be utilized at 2021-2022 USA Swimming events where testing is required.
  • "USA Swimming has prioritized athlete health and safety during this competitive season, emphasizing COVID-19 risk mitigation procedures," USA Swimming Director of Sports Medicine and Science Keenan Robinson said.
  • "BD's rapid antigen test, combined with a PCR test, will ensure accurate testing, helping keep everyone involved at USA Swimming safe and in the water."
  • Throughout the course of the U.S. Olympic Team Trials Swimming, more than 2,000 tests using the BD Veritor Plus System will be administered.

LivFul and Global Access Diagnostics announce partnership for COVID-19 test kit distribution

Wednesday, June 9, 2021 - 11:14am

LIVERPOOL, England, June 9, 2021 /PRNewswire/ --LivFul and Global Access Diagnostics (GAD)today announced a new partnership to make a variety of diagnostic kits, starting with COVID-19 rapid antigen tests, available in Low to Middle Income Countries.

Key Points: 
  • LIVERPOOL, England, June 9, 2021 /PRNewswire/ --LivFul and Global Access Diagnostics (GAD)today announced a new partnership to make a variety of diagnostic kits, starting with COVID-19 rapid antigen tests, available in Low to Middle Income Countries.
  • This partnership will bring rapid antigen test kits to the market at an affordable price.
  • We are aligned in driving access to our COVID-19 antigen test for as many people as possible."
  • "LivFul was founded to expand health access with products that transform lives and business models that reach all people.

MHRA Confirms Registration of Avacta’s AffiDX® SARS-CoV-2 Antigen Lateral Flow Test

Monday, June 7, 2021 - 8:51am

Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that the MHRA has confirmed registration of Avactas AffiDX SARS-CoV-2 antigen lateral flow test allowing the Company to place the product on the market in the UK for professional use.

Key Points: 
  • Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that the MHRA has confirmed registration of Avactas AffiDX SARS-CoV-2 antigen lateral flow test allowing the Company to place the product on the market in the UK for professional use.
  • Lateral flow antigen tests are intended to provide a cost effective and rapid means of identifying individuals with a high viral load that means they are more likely to infect others.
  • The clinical data for Avactas AffiDX SARS-CoV-2 antigen lateral flow test reported in April demonstrated 100% sensitivity for identifying infectious individuals with viral loads measured by PCR of Ct
  • Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: I am delighted to receive confirmation of the registration of the AffiDX SARS-CoV-2 antigen test from the MHRA.

iXensor Launches CE-marked Fully Digitized PixoTest COVID-19 Rapid Test with Digital Health Pass to Facilitate Safe Reopening of Economies

Thursday, June 3, 2021 - 10:00am

TAIPEI, June 3, 2021 /PRNewswire/ -- iXensor Co., Ltd. (6734.TWO),the pioneer of mobile health, announces that its PixoTest POCT COVID-19 Antigen Test has received the CE-IVD mark.

Key Points: 
  • TAIPEI, June 3, 2021 /PRNewswire/ -- iXensor Co., Ltd. (6734.TWO),the pioneer of mobile health, announces that its PixoTest POCT COVID-19 Antigen Test has received the CE-IVD mark.
  • The PixoTest POCT COVID-19 Antigen Test provides the end-to-end fully digitalized rapid screening solution to prevent further outbreaks.
  • iXensor's PixoTest solution comprises a palm-sized analyzer that reads test results accurately, a digital health pass App, an Admin App, and a HIPAA-grade health management web portal.
  • Concurrent reporting and digital health pass issuance:
    The analyzer transmits test results simultaneously to the PixoHealth Pass App users via an encrypted QR code.

iXensor Launches CE-marked Fully Digitized PixoTest COVID-19 Rapid Test with Digital Health Pass to Facilitate Safe Reopening of Economies

Thursday, June 3, 2021 - 5:46am

TAIPEI, June 3, 2021 /PRNewswire/ -- iXensor Co., Ltd. (6734.TWO),the pioneer of mobile health, announces that its PixoTest POCT COVID-19 Antigen Test has received the CE-IVD mark.

Key Points: 
  • TAIPEI, June 3, 2021 /PRNewswire/ -- iXensor Co., Ltd. (6734.TWO),the pioneer of mobile health, announces that its PixoTest POCT COVID-19 Antigen Test has received the CE-IVD mark.
  • The PixoTest POCT COVID-19 Antigen Test provides the end-to-end fully digitalized rapid screening solution to prevent further outbreaks.
  • iXensor's PixoTest solution comprises a palm-sized analyzer that reads test results accurately, a digital health pass App, an Admin App, and a HIPAA-grade health management web portal.
  • Concurrent reporting and digital health pass issuance:
    The analyzer transmits test results simultaneously to the PixoHealth Pass App users via an encrypted QR code.

AvantGen receives an award from the NIH/RADx to commercialize its anti-SARS-CoV-2 nucleocapsid antibodies for ultra-high sensitivity lateral flow assay development

Tuesday, May 25, 2021 - 11:00am

A pair of the antibody clones has been evaluated extensively in a rapid lateral flow assay (LFA) format for the detection of SARS-CoV-2 N protein.

Key Points: 
  • A pair of the antibody clones has been evaluated extensively in a rapid lateral flow assay (LFA) format for the detection of SARS-CoV-2 N protein.
  • The LFA test can detect N protein in clinical samples (n=55; Ct values 14-38) with 100% sensitivity.
  • We are extremely pleased to see that our rapid test exhibits an ultra-high sensitivity similar to that of the CDCs PCR test.
  • With the funding from RADx, we look forward to the further development of rapid antigen tests with these antibodies.

Global Rapid Antigen Detection Tests Industry (2020 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com

Tuesday, May 25, 2021 - 9:49am

The "Rapid Antigen Detection Tests - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rapid Antigen Detection Tests - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Rapid Antigen Detection Tests estimated at US$199.9 Million in the year 2020, is projected to reach a revised size of US$355.9 Million by 2027, growing at a CAGR of 8.6% over the period 2020-2027.
  • The U.S. Market is Estimated at $54 Million, While China is Forecast to Grow at 13% CAGR
    The Rapid Antigen Detection Tests market in the U.S. is estimated at US$54 Million in the year 2020.
  • Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.7% and 7.7% respectively over the 2020-2027 period.

eMed Donates 1,000 COVID-19 Rapid Antigen Tests for the Benefit of M-DCPS Students, Teachers and Families

Thursday, May 20, 2021 - 7:47pm

"Helping communities in need attain greater access to rapid antigen testing is part of the solution we can all contribute to as we move forward and transition into a post-pandemic \'transformed normal\'.

Key Points: 
  • "Helping communities in need attain greater access to rapid antigen testing is part of the solution we can all contribute to as we move forward and transition into a post-pandemic \'transformed normal\'.
  • "The distribution of these COVID-19 test kits will contribute to the wellbeing of our community and allow us to continue moving toward a sense of normalcy.
  • "This partnership provides an additional resource for supporting our students and families during such difficult times so that they can overcome this pandemic and return to normalcy.
  • We embrace quantitative medicine to deliver prescribed tests and treatments directly to patients, driving better and more cost-effective health outcomes.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/emed-donates-1-000-covid-19-rapi...\n'

Numi Health Provides COVID-19 Testing for Suncor Energy Workers Departing From Edmonton International Airport

Monday, May 17, 2021 - 2:00pm

b'CALGARY, Alberta, May 17, 2021 (GLOBE NEWSWIRE) -- Numi Health Inc. (Numi) is pleased to announce a community partnership involving Suncor Energy (Suncor), Edmonton International Airport (EIA) and Alberta Health Services (AHS), in which Numi provides rapid COVID-19 antigen testing for those travelling by air to Suncor\xe2\x80\x99s worksites in northern Alberta.\nSince late April, Numi has been providing rapid antigen testing for Suncor workers each week on charter flights departing from EIA to northern Alberta.

Key Points: 
  • b'CALGARY, Alberta, May 17, 2021 (GLOBE NEWSWIRE) -- Numi Health Inc. (Numi) is pleased to announce a community partnership involving Suncor Energy (Suncor), Edmonton International Airport (EIA) and Alberta Health Services (AHS), in which Numi provides rapid COVID-19 antigen testing for those travelling by air to Suncor\xe2\x80\x99s worksites in northern Alberta.\nSince late April, Numi has been providing rapid antigen testing for Suncor workers each week on charter flights departing from EIA to northern Alberta.
  • \xe2\x80\x9cRapid antigen testing provides results in as little as 15 minutes, allowing employees to return to work while minimizing concern about contracting or spreading the virus.
  • We are proud to deliver this industry-leading program to protect the health of Suncor\xe2\x80\x99s team in the field.\xe2\x80\x9d\nThe Suncor project builds on the success of Numi\xe2\x80\x99s screening program for airport workers and travellers.
  • As EIA\xe2\x80\x99s official COVID-19 testing partner, Numi has been screening hundreds of individuals each week at a pop-up clinic in the main terminal building.